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Arrhythmogenic Right Ventricular Cardiomyopathy
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Hartford, Connecticut and Rome, Italy
Arrythmogenic right ventricular (RV) cardiomyopathy (ARVC) is a cardiomyopathy char-
acterized pathologically by fibrofatty replacement primarily of the RV and clinically by
life-threatening ventricular arrhythmias in apparently healthy young people. The prevalence
of the disease has been estimated at 1 in 5,000 individuals, although this estimate will likely
increase as awareness of the condition increases among physicians. Arrythmogenic RV
cardiomyopathy is recognized as a cause of sudden death during athletic activity because of its
association with ventricular arrhythmias that are provoked by exercise-induced catecholamine
discharge. Diagnosis may be difficult because many of the electrocardiographic abnormalities
mimic patterns seen in normal children, and the disease often involves only patchy areas of
the RV. For this reason, international diagnostic criteria for ARVC were proposed by an
expert consensus panel in 1996. Treatment is directed to preventing life-threatening cardiac
arrhythmias with medications and the use of implantable defibrillators. This article will
present in detail the etiology, clinical presentation, diagnosis and management of this
condition. (J Am Coll Cardiol 2001;38:1773–81) © 2001 by the American College of
Cardiology
Arrhythmogenic right ventricular (RV) cardiomyopathy
(ARVC) is a myocardial disease affecting primarily the RV
and characterized histologically by the gradual replacement
of myocytes by adipose and fibrous tissue. Diagnostic
criteria for ARVC were proposed in 1994 by an expert
consensus panel (1,2).
Arrhythmogenic RV cardiomyopathy is an important
cause of sudden death in individuals 30 years of age and
has been found in up to 20% of sudden deaths in young
people (2,3). Recently, there has been considerable interest
in ARVC as a cause of sudden death in young athletes, and
it is reported as the most common cause of exercise-related
sudden death among young Italian athletes (2).
DEFINITION
The term “ARVC” was first proposed by Fontaine et al. (4)
in a 1977 report describing six patients with sustained
ventricular tachycardia (VT) who did not have overt heart
disease and were resistant to antiarrhythmic drugs. Early
reports have emphasized the localized RV involvement, but
it is now clear that ARVC can progress to diffuse RV and
left ventricular (LV) involvement and may culminate in
biventricular heart failure (5,6). In this advanced stage,
ARVC is difficult to distinguish clinically from dilated
cardiomyopathy (7).
Genetics and family screening. The prevalence of ARVC
in the general population is approximately 1 in 5,000 (8),
but the disease is not widely recognized because of the
difficulty in making the diagnosis (9). A familial predilection
of the disease has been recognized since 1982 when Marcus
et al. (10) described 24 cases of ARVC, two in the same
family. Subsequently, several groups have reported familial
ARVC, and families with two or more affected individuals
have been recognized in Asian, Japanese, Northern Euro-
pean, African and North American populations (8).
The disease is typically inherited as an autosomal domi-
nant trait with variable penetrance and incomplete expres-
sion. The genes responsible for ARVC have not been
identified, but seven loci have been mapped to chromo-
somes 14 (14q23 to q24 and 14q12 to q22), 1 (1q42 to q43),
2 (2q32.1 to q32.2), 3 (3p23) and 10 (10p12 to p14)
(2,11–13). The genetic products of these sites have not been
easily identified because of incomplete penetrance and
expression, age-related expression and difficulties with ac-
curate diagnosis of the disease. Recently, plakoglobin has
been identified as the first gene responsible for autosomal
recessive ARVC (13). The gene was identified in Naxos
disease where greater than 90% cosegregation of ARVC
with cutaneous manifestations, woolly hair and keratoder-
mia, facilitated case identification. Plakoglobin participates
in forming cell-to-cell junctions. It is postulated that inad-
equate cell adherence damages the cardiac cell membranes
leading to cell death and fibrofatty replacement.
The cardiac ryanodine receptor gene (RyR2) has also
recently been implicated in ARVC (14) and offers potential
insight into the association of adrenergically mediated
ventricular arrhythmias with this disease. The ryanodine
receptor induces calcium release from the sarcoplasmic
reticulum into the cytosol (14). The cardiac ryanodine
receptor has also been identified as being responsible for
catecholamine-induced ventricular tachycardia (15,16). Its
skeletal muscle counterpart has been implicated in malig-
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nant hyperthermia and central core disease (17), a congen-
ital myopathy, but the mechanisms by which mutations in
the cardiac ryanodine receptor might mediate fibrofatty
myocardial changes are not clear and will likely be the focus
of future studies. Despite these advances, genetic analysis
for ARVD is not clinically available and is restricted to
research laboratories.
Histopathology. Characteristically, the RV in ARVC is
replaced with a fibrofatty tissue. Morphologic alterations of
ARVC usually begin in the subepicardium or mediomural
layers (8,18) of the RV and progress to the endocardium
with fibrofatty replacement of myocytes and thinning of the
wall. The regions of RV most frequently involved are the
RV inflow area, the apex and the infundibulum. These three
areas form “the triangle of dysplasia” (2,19). However, small
amounts of fat are present in the epicardial layer and within
the RV myocardium in normal subjects. Fontaine et al. (20)
examined the hearts at necropsy in 140 individuals with no
history of heart disorders. Over 50% of the subjects had fat
within their RV myocardial fibers, and the presence of
intramyocardial fat increased with age. Therefore, histologic
diagnosis of ARVC may be difficult in borderline cases. To
avoid overdiagnosing ARVC, Angeline et al. (21) have
proposed that the presence in biopsy sections of more than
3% of fibrous tissue and more than 40% of fatty tissue is
highly suggestive of ARVC. These authors also emphasized
the importance of identifying coexisting myocardial fibrosis
in making the diagnosis. In a forensic autopsy study of 20
patients with ARVC who died suddenly (22), the fatty
replacement involved the outer half of RV free wall in 27%,
the outer two-thirds in 28% and the entire wall thickness in
45% of the cases. Interestingly, the endocardial muscular
trabeculae are generally spared but may occasionally also be
atrophied (22,23). The LV was involved in 40% of cases in
this report (22), although other reports have identified LV
involvement in up to 76% of individuals with ARVC
examined at necropsy (6). When the LV is involved, the
fibrofatty replacement can affect both the septum and LV
free wall, either diffusely or, more often, regionally with a
predilection for the posteroseptal and posterolateral areas.
In the LV, fatty replacement of the myocardium has a
predilection for the subepicardial and midventricular wall
(6).
ETIOLOGY
In addition to a genetic cause of ARVC, disontogenetic
(19,23), degenerative (23,24), infectious or inflammatory
(25–28), apoptotic (29,30) and myocyte transdifferentiation
(31) theories have been proposed either as the cause of or as
environmental factors facilitating gene expression.
The disontogenetic theory is largely historical but sug-
gests that ARVC is a milder form of “parchment RV” or
Uhl’s anomaly (19,23), a congenital hypoplasia of the RV
myocardium, which presents in infancy as congestive heart
failure (CHF) (32).
The degenerative theory suggests that ARVC is a conse-
quence of myocyte death due to an inherited metabolic or
ultrastructural defect. A possible defect has been mapped to
chromosome l4q23 to q24 (33). This area encodes for the
alpha actinin gene, which shares structural homology with
the amino terminal domain of dystrophin. This finding
supports the concept of a genetically determined atrophy
similar to that in patients with Duchenne’s or Becker’s
muscular dystrophy. Some have suggested that ARVC
should be considered as a “myocardial dystrophy” (23).
Furthermore, skeletal muscle involvement has been reported
in a Swedish family with ARVC, and the defect has been
tentatively localized to chromosome 10q22.3 (34).
The infectious or inflammatory theory maintains that the
disease results from previous myocarditis. Inflammatory
infiltrates are common in histologic specimens from patients
with ARVC. Fontaine et al. (25) found inflammatory
infiltrates in 8 of 27 patients with ARVC. BALB/C mice
infected with Coxsackie virus B3 develop selective RV
myocardial cell death, acute mononuclear cell infiltration
and subsequent RV aneurysm formation (27). Furthermore,
enteroviral RNA with homology to Coxsackie viruses type
B has been detected in three of eight patients with ARVC
and in 7 of 23 patients with myocarditis or dilated cardio-
myopathy (28).
An apoptotic theory is supported by the finding of
apoptosis and a high level of CPP-32, a cysteine protease
required for apoptosis, which were detected in the RV
myocardium of six of eight patients with ARVC but not in
four normal subjects (29,30).
The transdifferentiation theory is based on the hypothesis
that myocardial cells can change from muscle to adipose
tissue and the observation in one patient that “transitional
cells” at the interface between cardiac muscle and adipose
tissue expressed both desmin, which is characteristic of muscle
tissue, and vimentin, expressed only in adipocytes (31).
CLINICAL PRESENTATION
Arrhythmogenic RV cardiomyopathy typically occurs in
young adult men. At least 80% of cases are diagnosed before
Abbreviations and Acronyms
ARVC arrhythmogenic right ventricular
cardiomyopathy
CHF  congestive heart failure
CT  computerized tomography
ECG  electrocardiogram
ICD  implantable cardioverter defibrillator
LV  left ventricle or left ventricular
MRI  magnetic resonance imaging
NSVT  nonsustained ventricular tachycardia
PVC  premature ventricular complex
RBBB  right bundle branch block
RV  right ventricle or right ventricular
RVOT right ventricular outflow tachycardia
VT  ventricular tachycardia
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the age 40. Arrhythmogenic RV cardiomyopathy should be
considered in young patients presenting with syncope, VT,
cardiac arrest or in adult patients with CHF (35).
Arrhythmia. The VT in patients with ARVC usually has a
left bundle branch block morphology, reflecting origin of
the arrhythmia from the RV. Some patients have multiple
VT morphologies because the disease can produce multiple
arrhythmogenic foci. Many relatives of ARVC probands
have a history of syncope that is undiagnosed, in part
because they lack other features suggestive of ARVC. This
has been labeled “concealed ARVC” (2,36). Many of these
cases subsequently develop progressive electrocardiogram
(ECG) changes typical of ARVC and are then labeled as
“revealed ARVC” (8).
Sudden death. In the U.S., ARVC accounts for approxi-
mately 5% of sudden cardiac deaths in individuals under the
age of 65 (37) and is responsible for at least 3% to 4% of
deaths associated with physical activity in young athletes
(38). In the Veneto region of Italy, ARVC is the most
common cause of sudden arrhythmic deaths in individuals
under the age of 35 years and the overwhelming cause of
sudden death associated with exertion in young athletes in
Italy (12,26,39). The annual mortality rate of ARVC has
been estimated at 3% without treatment and at 1% with
pharmacologic medical treatment not including implanted
automatic defibrillators (40). The mechanism of sudden
death in ARVC is, in most cases, acceleration of VT with
degeneration into ventricular fibrillation.
Peters et al. (41) sought to identify patients with ARVC
who were at greatest risk of cardiac arrest. They analyzed
angiographic and electrophysiologic data from 60 patients
with documented ARVC. Twenty had spontaneous non-
sustained VT (NSVT); 27 had sustained VT, and 13
suffered cardiac arrest with documented ventricular fibrilla-
tion. Global RV function was reduced in patients with
cardiac arrest, and the reduction was most pronounced in
those cases with cardiac arrest and inducible ventricular
arrhythmia. Hypokinetic segments as well as end-diastolic
and end-systolic bulges were also more frequent in patients
who had suffered a cardiac arrest and had an inducible
ventricular arrhythmia. Approximately 40% of the patients
had LV wall motion abnormalities despite normal global
LV function (mean LV ejection fraction 60  11%). These
patients did not have an increased incidence of spontaneous
ventricular arrhythmia. The authors concluded that func-
tional and structural worsening of RV performance was the
major risk factor for cardiac arrest in patients with ARVC.
Triggering events and mechanisms of arrhythmias. The
islands of fibrofatty tissue found in ARVC generate macro
reentry electrical circuits and form the arrhythmogenic
substrate for the malignant cardiac arrhythmias responsible
for sudden death in these patients. These arrhythmias are
typically induced by adrenergic stimulation such as catechol-
amine infusion or physical exercise (42). Most patients with
ARVC are susceptible to adrenergic stimulation, and 80%
develop either ventricular extrasystoles or VT during iso-
prenaline infusion (43). Additional evidence supports the
concept that VT in ARVC is due to sympathetic stimula-
tion. Ambulatory ECG recordings of patients developing
sustained VT demonstrate a progressive increase in the sinus
rate before the onset of the arrhythmia, suggesting progres-
sive sympathetic stimulation (43). Ventricular tachycardia in
ARVC is characteristically monomorphic and rarely initi-
ated by complexes of a different configuration, suggesting
that the arrhythmia originates from a single focus. This
contrasts with the monomorphic VT observed in patients with
coronary artery disease, which is often initiated by premature
ventricular complexes (PVC) from a different focus. The role of
sympathetic stimulation in provoking arrhythmias in ARVC
probably accounts for the high prevalence of this condition in
individuals who die during exertion.
Heart failure. Patients with ARVC may develop isolated
right heart failure or biventricular failure. This presentation
of ARVC typically appears in the fourth and fifth decades of
life (8). Arrhythmogenic RV cardiomyopathy is one of the
few myocardial diseases that causes RV heart failure without
pulmonary hypertension. The mechanism for the RV failure
is dilation, thinning of the wall and progressive loss of
contractile function because of myocardial atrophy. Right
heart failure typically presents in ARVC four to eight years
after the appearance of complete right bundle branch block
(RBBB) on the ECG (37). Arrhythmogenic RV cardiomy-
opathy can involve the LV and produce mild decreases of
LV function, although left-sided heart failure is unusual.
When left heart failure does occur, it may be misdiagnosed
as idiopathic or viral dilated cardiomyopathy (8). Left-sided
dysfunction in ARVC may represent “biventricular dyspla-
sia” and must be differentiated from biventricular myocar-
ditis with fibrosis (27). Making the correct diagnosis is
important since patients with ARVC tend to be more
susceptible to drug-resistant arrhythmia and sudden death
and may require other treatment options such as an auto-
matic implantable cardioverter defibrillator (ICD) or cardiac
transplantation. Clinicians should consider the possibility of
ARVC if the patient has an apparent dilated cardiomyop-
athy with a resting ECG showing right precordial T-wave
changes.
DIAGNOSIS
A definite diagnosis of ARVC requires the histologic
finding of transmural fibrofatty replacement of RV myocar-
dium at necropsy (Fig. 1), surgery or endomyocardial biopsy
(Fig. 2). Diagnosis by endomyocardial biopsy is difficult,
however, because the disease is segmental and because the
interventricular septum, the area usually biopsied, is rarely
involved (1). Because of the difficulty in establishing a
diagnosis, an expert consensus group has proposed criteria
for the diagnosis (Table 1). To qualify as ARVC, a patient
must demonstrate either two major criteria, one major
criteria plus two minor criteria or four minor criteria (1).
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ECG findings. Repolarization abnormalities manifested
by T-wave inversion in leads V1 to V3 in the absence of a
complete RBBB are a minor diagnostic criterion but are
extremely useful in raising the suspicion of ARVC and are
present in up to 54% of cases (18) (Fig. 3). This finding is
difficult to differentiate from normal findings, however,
because many children and young subjects have T-wave
inversions in the right precordial leads, and this is conse-
quently a diagnostic criterion only in individuals 12 years
old (44). Furthermore, young, trained athletes also may
demonstrate ECG patterns consistent with ARVC in the
absence of pathologic cardiac conditions (45). The presence
of marked T-wave inversions in all precordial leads corre-
lates with LV involvement (18) and, in patients with
ventricular arrhythmias, indicates a high risk of recurrence.
Some patients demonstrate signs of depolarization delay
such as RBBB or incomplete RBBB, although these pat-
terns alone are not criteria for the diagnosis because they can
be found not uncommonly in healthy subjects. Complete
RBBB is found in approximately 15% of patients with
ARVC, and incomplete RBBB is observed in 18% (18).
Along with the conduction delay, there may also be low
voltage in the rapid phase of the QRS related to the loss of
RV myocardium. Selective prolongation of the QRS in
leads V1 to V3 compared with lead V6 is an additional major
criterion and is satisfied if the QRS duration in leads V1 to
V3 is 50 ms above the QRS duration in lead V6 in the
presence of RBBB (46).
Figure 1. Heart of a 37-year-old woman admitted with heart failure who suffered a subsequent cardiac arrest. The arrow identifies fatty infiltration of the
right ventricle.
Figure 2. Trichrome-stained section from the right ventricle of the patient
from Figure 1 showing increasing fibrous and adipose tissue throughout the
ventricular wall (200).
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Epsilon waves are a major diagnostic criterion that are
found in up to 30% of cases of ARVC (5,18). Epsilon waves
are “postexcitation” electrical potentials of small amplitude
that occur at the end of the QRS complex and at the
beginning of the ST segment (Fig. 4). They are highly
specific for ARVC and reflect delayed RV activation. Peters
et al. (27) found that maximum QRS duration in right
precordial leads of 110 ms and left precordial JT interval
prolongation characterized quantitatively by a JT interval
dispersion of30 ms represented a noninvasive predictor of
recurrent arrhythmic events. The presence of RBBB on
ECG with QRS precordial dispersion 50 ms generally
characterized patients with massive RV dilation and recur-
rent episodes of VT or ventricular fibrillation.
Signal-averaged ECG. Late action potentials on signal-
averaged ECG recordings are a minor criterion for the
diagnosis of ARVC. Late action potentials on the signal-
averaged ECG are the counterpart of the epsilon waves
recorded on the surface ECG. Consistent with other ECG
abnormalities in ARVC, the abnormalities on signal-
averaged ECG are more prominent in the right precordial
leads than they are in the left precordial leads (5).
Between 50% to 80% of patients with ARVC and clinical
VT have an abnormal signal-averaged ECG (47,48). The
signal-averaged ECG may be normal if the disease is
localized to a small segment of the RV, but such patients are
not immune to malignant arrhythmias. Abnormal signal-
averaged ECG recordings are more common in patients
with more severe myocardial fibrosis and reduced RV
ejection fraction and predict sustained VT among ARVC
patients with prior nonsustained VT (47).
Echocardiographic findings. Echocardiography can be
used to evaluate RV and LV size and function, which are
important major and minor criteria for the diagnosis of
ARVC. The most prevalent finding is a severely hypokinetic
and dilated RV, although the spectrum of abnormalities
may range from a normal RV to severe RV dilation and
hypokinesis (49). Generally, the structural abnormalities in
ARVC are moderate and easily overlooked. The most
suggestive echocardiographic findings for ARVC include
dilation of the RV, with localized aneurysms during diastole
and dyskinesis in the inferior basal region (18). The RV
function should be measured at several points including the
RV inflow tract, body and outflow tract regions because of
the focal nature of the disease (50). The most important
other echocardiographic parameters in establishing the di-
agnosis are the RV end-diastolic and end-systolic diameters,
as well as the ratio of the RV to LV end-diastolic diameters.
A ratio of 0.5 for the RV/LV end-diastolic diameter has
a sensitivity of 86%, a specificity of 93% and a positive
predictive value of 86% for the diagnosis of ARVC (5).
The negative predictive value is 93%, making this param-
eter an extremely useful diagnostic measurement. More
extreme RV compared with LV dilation is even more
suggestive of ARVC. Manyari et al. (51) found that all of 14
patients with RV cardiomyopathy had an RV/LV end-
diastolic volume ratio 1.8 or an exercise RV ejection
fraction 50%. Subtle findings include localized abnormal-
ities of right heart cavity such as increased reflectivity of the
Table 1. Criteria for Diagnosis of RV Dysplasia
I. Global or regional dysfunction and structural alterations*
MAJOR
Severe dilation and reduction of RV ejection fraction with no (or only
mild) LV impairment.
Localized RV aneurysms (akinetic or dyskinetic areas with diastolic
bulging).
Severe segmental dilation of the RV.
MINOR
Mild global RV dilation or ejection fraction reduction with normal LV.
Mild segmental dilation of the RV.
Regional RV hypokinesia.
II. Tissue characterization of walls
MAJOR
Fibrofatty replacement of myocardium on endomyocardial biopsy.
III. Repolarization abnormalities
MINOR
Inverted T waves in right precordial leads (V2 and V3) (people aged
more than 12 yr; in absence of right bundle branch block).
IV. Depolarization/conduction abnormalities
MAJOR
Epsilon waves or localized prolongation (110 ms) of the QRS
complex in right precordial leads (V1 to V3).
MINOR
Late potentials (signal-averaged ECG).
V. Arrhythmia
MINOR
Left bundle branch block type ventricular tachycardia (sustained and
nonsustained) (ECG, Holter, exercise testing).
Frequent ventricular extrasystoles (more than 1,000/24 h) (Holter).
VI. Family history
MAJOR
Familial disease confirmed at necropsy or surgery.
MINOR
Familial history of premature sudden death (35 yr) due to suspected
RV dysplasia.
Familial history (clinical diagnosis based on present criteria).
*Detected by echocardiography, angiography, magnetic resonance imaging or radio-
nuclide scintigraphy
ECG  electrocardiogram; LV  left ventricle or left ventricular; RV  right
ventricle or right ventricular.
Figure 3. Electrocardiogram of a 32-year-old woman with arrhythmogenic
right ventricular cardiomyopathy showing right precordial T-wave inver-
sions.
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moderator band and prominent trabeculations of the RV
apex (18).
RV angiography. Right ventricular angiography is still
considered by many experts the method of choice for
evaluating RV function (5,18). The RV is best evaluated by
biplane angiography with views obtained in the 45° right
anterior oblique and 45° left anterior oblique to assess the
areas commonly involved in ARVC such as the infundibu-
lum, the anterior RV free wall and inferior wall, especially
the subtricuspid area (2,18). The RV angiogram should be
obtained during sinus rhythms without frequent PVCs.
Potential abnormal findings on RV angiography include
(18): infundibular aneurysms, trabeculae thicker than 4 mm
that give the appearance of “deep fissures,” a prominent
moderator band, apical aneurysms, multiple out pouchings
of the inferior wall, diastolic bulging of the subtricuspid area
and, in severe cases, tricuspid valve prolapse, usually asso-
ciated with mild tricuspid insufficiency. The coexistence of
subtricuspid and anterior infundibular wall bulging as well
as hypertrophic trabeculae is associated with 96% specificity
and 87.5% sensitivity for the diagnosis of ARVC (2,5).
Computerized tomography (CT) and magnetic reso-
nance imaging (MRI). Computerized tomography and
MRI have recently been added to the techniques used to
diagnose ARVC. Compared with conventional CT,
electron-beam CT provides superior temporal resolution
and enables better evaluation of the ventricle because of its
ability to acquire motionless cardiac and cross-sectional
images. Characteristic findings of ARVC on electron-beam
CT findings include abundant epicardial adipose tissue,
prominent trabeculations with low attenuation, a scalloped
appearance of the RV free wall and intramyocardial fat
deposits (9).
Magnetic resonance imaging is a potentially useful test
because it can distinguish fat from muscle. Cine MRI also
provides good contrast between the blood pool and the
myocardial wall and, therefore, can provide information
about RV wall motion and function (2,52). However, there
are some limitations to this technique. The RV free wall is
thin, resulting in insufficient spectral resolution to ade-
quately quantify the RV thickness, in addition to the normal
presence of epicardial and pericardial fat causing difficulty in
identifying intramyocardial fat (2,12).
MANAGEMENT OF PATIENTS WITH ARVC
Pharmacologic therapy. There are few studies evaluating
treatment strategies in asymptomatic patients with mild
morphologic RV alterations and no evidence of arrhythmia.
Beta-adrenergic blocking agents are a reasonable recom-
mendation in these patients to reduce the possibility of
adrenergically stimulated arrhythmia. In the presence of
arrhythmia (NSVT, VT or frequent and complex PVCs) or
symptoms, treatment should be initiated with beta-blockers
or ICD with additional medical therapy to prevent defibril-
lator discharge.
Wichter et al. (42) evaluated the effectiveness of sotalol in
81 patients who had either ARVC or RV outflow tachy-
cardia (RVOT). Sotalol prevented VT during programmed
ventricular stimulation in 68% of the patients, whereas class
Figure 4. Electrocardiogram (ECG) of an 18-year-old male patient diagnosed with arrhythmogenic right ventricular cardiomyopathy by cardiac
angiography and refractory ventricular tachycardia requiring a defibrillator. The ECG is magnified to demonstrate the epsilon waves (arrow). The QRS
duration is greater in the right ventricular leads than it is in V6. The ECG also shows biatrial enlargement.
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Ia and Ib drugs were effective in only 5.6% and class Ic drugs
in only 2% of patients. Patients unresponsive to sotalol were
unlikely to respond to amiodorone when evaluated by
programmed ventricular stimulation (5). In patients in
whom VT could not be induced during programmed
ventricular stimulation, efficacy was determined by suppres-
sion of ventricular arrhythmias during Holter monitoring
and exercise testing. Sotalol was again the most effective
drug, with 83% of patients responding. Verapamil was the
next most effective. No patients appeared to be responsive to
class Ia or Ib drugs, and only 17% responded to class Ic
drugs. Unfortunately, 10% of the patients had a repeated
episode of nonfatal VT during a follow-up period of 34
months, which raises the question as to whether even the
best antiarrhythmic agents are effective for long-term treat-
ment of symptomatic patients. In addition, other limitations
should be considered. It was not specified how many
patients had ARVC and how many had RVOT; the
prognosis in these two conditions are different, with ARVC
being much more life-threatening. The assignment of
patients to various antiarrhythmic therapies was not ran-
dom. Nevertheless, this study remains the largest examina-
tion in patients with RV tachycardia and provides some
guidance for the use of sotalol.
Amiodarone has both mild beta-blocking effects and
antiarrhythmic characteristics and has been effectively used
either alone or in combination with other agents to prevent
recurrent cardiac arrhythmia, but no studies have addressed
the use of amiodarone in this patient group (5).
Radiofrequency ablation. Radiofrequency ablation of an
arrhythmogenic focus can be attempted in patients who are
unresponsive or intolerant to antiarrhythmic drugs but is
frequently unsuccessful and may require multiple attempts.
Fontaine et al. (53) reported success rates of 32%, 45% and
66% after one, two or three ablation sessions in 50 patients,
most of whom had not had success with other therapy and
were followed for a mean of 5.4 years after ablation.
Ablation may be unsuccessful because of the progressive
nature of the disease and the diffuse, yet patchy, nature of
the disease, which produces multiple arrhythmogenic foci.
Consequently, ablation of one focus may unmask other
arrhythmogenic areas (5).
ICD. Patients who are considered to be at high risk for
sudden cardiac death should receive an ICD. This includes
patients who have been resuscitated from cardiac arrest,
with history of syncope or who have threatening arrhyth-
mias that are not completely suppressed by antiarrhythmic
drug therapy. The risk of sudden death in such patients is
increased and should prompt consideration of ICD implan-
tation.
Nevertheless, this approach does not imply that there are
no risks to the implantation in patients with ARVC. First,
areas of the RV myocardium in patients with ARVC are
thin and noncontractile and can be penetrated during
placement of the RV leads with subsequent tamponade.
Second, the fibrofatty nature of the RV may lead to
difficulty in the device adequately sensing arrhythmias with
improper ICD function or failure (54).
Sudden death in competitive athletes with ARVC. Ar-
rhythmogenic RV cardiomyopathy has been recognized as
an important cause of sudden death in association with
exercise and athletic participation. Its frequency as a cause of
such exercise-related events in some reports is related to its
prevalence, its predilection to produce malignant ventricular
arrhythmias in young subjects and the fact that these
arrhythmias are often provoked by adrenergic stimulation.
Furlanello et al. (55) examined 1,642 competitive athletes
referred for cardiac arrhythmia detected as part of a national
preparticipation athletic screening program in Italy. A total
of 6% were diagnosed with ARVC using World Health
Organization criteria. These athletes were followed for an
average of eight years, and 4% of them suffered either a
cardiac arrest or sudden death. Individuals with ARVC
comprised 23% and 25% of all athletes suffering either a
cardiac arrest or sudden death, confirming that ARVC is the
dominant cause of exercise-related sudden death among
Italian athletes. All cardiac arrests in athletes with ARVC
occurred during athletic activity, supporting the importance
of exercise-induced adrenergic stimulation in provoking
malignant arrhythmias in these patients. More than 60% of
the patients with ARVC had important prodromal symp-
toms such as syncope before their collapse; these prodromal
symptoms were also related to athletic activity but did not
lead to a premortem diagnosis and appropriate treatment.
Because of the risk of sudden death in patients with
ARVC, young subjects with this condition should be
prohibited from vigorous athletic competition (56). This
prohibition remains in effect even after the subjects have
received effective treatment such as in ICD placement
because athletic competition may induce incessant ventric-
ular fibrillation that cannot be terminated, given the re-
sponse patterns of present devices. Specifically, most devices
are programmed to deliver a total of six shocks. If the
arrhythmia persists, additional shocks will not be delivered
without an interval period of sinus rhythm to prevent
recurrent shocking of an artifact pattern.
Conclusions. Arrhythmogenic RV cardiomyopathy is in-
creasingly recognized as a cause of malignant ventricular
arrhythmias among apparently healthy young subjects and
individuals engaged in vigorous exercise. Physicians should
consider this condition in young subjects with cardiac
arrhythmias or unexplained cardiomyopathy. Management
involves the suppression of malignant arrhythmias with
various pharmacologic agents but is increasingly directed
toward placement of automatic implantable defibrillators as
the most effective treatment to prevent sudden cardiac
death.
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